Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.775
+0.105 (2.86%)
At close: Oct 5, 2026, 4:00 PM EDT
3.770
-0.005 (-0.13%)
After-hours: Oct 5, 2026, 4:10 PM EDT
Prelude Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Prelude Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.20. The average 1-year stock price forecast is 143.71% higher than the current stock price, while the lowest is $6.00 (+58.94%) and the highest is $12 (+217.88%).
Price Target: $9.20 (+143.71%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Initiates $12 | Buy | Initiates | $12 | +217.88% | Sep 17, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $8 | Buy | Reiterates | $8 | +111.92% | Jul 29, 2026 |
| D. Boral Capital | D. Boral Capital | Buy Initiates $9 | Buy | Initiates | $9 | +138.41% | May 4, 2026 |
Financial Forecast
Revenue This Year
43.56M
from 12.14M
Increased by 258.83%
Revenue Next Year
41.77M
from 43.56M
Decreased by -4.10%
EPS This Year
-0.58
from -1.29
EPS Next Year
-0.55
from -0.58
EPS and Forward PE are based on non-GAAP adjusted numbers.